Syndax Pharmaceuticals SNDX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$42.67M+37.3% | -$68.01M-12.0% | -$60.72M+15.5% | -$71.85M+15.3% | -$84.85M+9.9% | ||
| $12.05M+7.1% | $11.25M-6.9% | $12.08M-12.4% | $13.79M+32.8% | $10.38M-15.6% | ||
| $56K— | $0-100% | $62K+12.7% | $55K-50.9% | $112K+273% | ||
| -$120K-101% | $12.59M+112% | $5.95M+59.4% | $3.73M-54.0% | $8.12M+6.8% | ||
| $2.06M-73.6% | $7.8M+8.6% | $7.18M-44.4% | $12.92M+208% | $4.19M+1,045% | ||
| -$5.74M-308% | $2.75M— | —— | $7.31M+563% | -$1.58M-123% | ||
| -$28.35M-210% | $25.7M+2,232% | $1.1M-93.8% | $17.9M+807% | -$2.53M-122% | ||
| -$7.84M-245% | $5.4M+23.7% | $4.36M-59.5% | $10.77M+280% | -$5.99M— | ||
| —— | $0— | —— | —— | —— | ||
| -$6.14M-196% | $6.4M+16,753% | $38K-2.6% | $39K+187% | -$45K-135% | ||
| -$50.35M+27.5% | -$69.49M+1.5% | -$70.54M+19.7% | -$87.8M+7.7% | -$95.16M-65.8% | ||
| $39.39M-37.6% | $63.12M+107% | $30.44M-66.8% | $91.71M+770% | $10.54M-97.2% | ||
| $77.78M-46.3% | $144.75M+40.5% | $103M-22.9% | $133.6M+27.6% | $104.68M-2.5% | ||
| $38.39M-52.9% | $81.58M+12.6% | $72.43M+72.9% | $41.89M-55.5% | $94.14M+135% | ||
| $7.92M+33.8% | $5.92M-5.8% | $6.28M+1,039% | $551K-40.8% | $930K-99.7% | ||
| -$4.04M— | —— | —— | -$45.36M-50,297% | -$90K— | ||
| $862K-43.7% | $1.53M-36.6% | $2.41M-24.9% | $3.21M-10.8% | $3.6M+22.4% | ||
| $56K— | $0-100% | $62K+12.7% | $55K-50.9% | $112K+273% | ||
| $4K+33.3% | $3K0.0% | $3K— | $0— | $0— | ||
| -$6.14M-196% | $6.4M+16,753% | $38K-2.6% | $39K+187% | -$45K-135% | ||
| -$28.35M-210% | $25.7M+2,232% | $1.1M-93.8% | $17.9M+807% | -$2.53M-122% | ||
| $3.24M+140% | -$8.01M-134% | -$3.42M+86.0% | -$24.5M-248% | -$7.04M-151% | ||
| -$7.84M-245% | $5.4M+23.7% | $4.36M-59.5% | $10.77M+280% | -$5.99M— | ||
| —— | $40.75K0.0% | $40.75K0.0% | $40.75K0.0% | $40.75K— | ||
| $130K-67.1% | $395K+150% | $158K-8.1% | $172K-22.2% | $221K+6.3% | ||
| —— | $916.75K0.0% | $916.75K0.0% | $916.75K0.0% | $916.75K— | ||
| $39.39M-37.6% | $63.12M+107% | $30.44M-66.8% | $91.71M+770% | $10.54M-97.2% | ||
| $77.78M-46.3% | $144.75M+40.5% | $103M-22.9% | $133.6M+27.6% | $104.68M-2.5% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $458K-24.3% | $605K— | $0-100% | $468K-14.1% | $545K-14.0% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $0— | $0— | $0— | $0-100% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Syndax Pharmaceuticals's cash flow data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.